Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results

Fri Jan 18, 2013 4:02pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

THOUSAND OAKS, Calif.,  Jan. 18, 2013  /PRNewswire/ -- Amgen (NASDAQ:AMGN) today
announced that it will report its fourth quarter and full year 2012 financial
results on  Wednesday, Jan. 23, 2013, after the close of the financial markets.
The announcement will be followed by a conference call with the investment
community at  2:00 p.m. Pacific Standard Time. Participating in the call from
Amgen will be  Robert A. Bradway, chairman and chief executive officer, and
other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the
Internet and will be available to members of the news media, investors and the
general public.  

The webcast of the conference, as with other selected presentations regarding
developments in Amgen's business given by management at certain investor and
medical conferences, can be found on Amgen's website,, under
Investors. Information regarding presentation times, webcast availability and
webcast links are noted on Amgen's Investor Relations Events Calendar. The
webcast will be archived and available for replay for at least 30 days after the

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping millions of people around the world in
the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and
other serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and vital medicines,
visit Follow us on  

CONTACT: Amgen,  Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)



Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.